Results 201 to 210 of about 183,644 (348)

Angiotensin II Type 1 Receptor Blocker Usage Prevents Oxidative Stress and Muscle Dysfunction in HIV. [PDF]

Fundam Clin Pharmacol
Deminice R, Cella PS, Borsari AL, Padilha CS, de Oliveira VHF.   +4 more
europepmc   +1 more source

Angiotensin II type-1 receptor-associated protein interacts with transferrin receptor-1 and promotes its internalization. [PDF]

Sci Rep, 2022
Abe E, Yamashita A, Hirota K, Yamaji T, Azushima K, Urate S, Suzuki T, Tanaka S, Taguchi S, Tsukamoto S, Uehara T, Wakui H, Tamura K, Takahashi H.   +13 more
europepmc   +1 more source

A Delphi consensus project to capture experts' opinion on hyperkalaemia management across the cardiorenal spectrum

ESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.
Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou, Maria Marketou, Maria Aktsiali, Ioannis Griveas   +3 more
wiley   +1 more source

Temporal complexity of LVV-hemorphin-7 allosterism at the angiotensin II type 1 receptor assessed using entropy-based approaches. [PDF]

Comput Struct Biotechnol J
Jelinek HF, Johnson MP, Khan FB, Elgendi M, Ayoub MA.   +4 more
europepmc   +1 more source

Author Correction: Angiotensin II type-1 receptor-associated protein interacts with transferrin receptor-1 and promotes its internalization. [PDF]

Sci Rep, 2022
Abe E, Yamashita A, Hirota K, Yamaji T, Azushima K, Urate S, Suzuki T, Tanaka S, Taguchi S, Tsukamoto S, Uehara T, Wakui H, Tamura K, Takahashi H.   +13 more
europepmc   +1 more source

SUPPRESSION OF ADVANCED GLYCATION AND LIPOXIDATION END PRODUCTS BY ANGIOTENSIN II TYPE-1 RECEPTOR BLOCKER CANDESARTAN IN TYPE 2 DIABETIC PATIENTS WITH ESSENTIAL HYPERTENSION

, 2013
Yoshiaki Ōno, Kenji Mizuno, Michihiko Takahashi, Yukio Miura, Tsuyoshi Watanabe   +4 more
openalex   +2 more sources

DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.

Endocrine journal, 2014
H. Fujita, Hisanori Taniai, H. Murayama, Haruyo Ohshiro, Hikaru Hayashi, Seiko Sato, Nyuko Kikuchi, Taiga Komatsu, K. Komatsu, Kanji Komatsu, T. Narita, Yuichiro Yamada   +11 more
semanticscholar   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Angiotensin II type 1 receptor antibodies as a contributor to microvascular inflammation in kidney transplant recipients: insights from statistical and artificial intelligence based approaches. [PDF]

Front Immunol
Mizera J, Donizy P, Halon A, Janczak D, Kepinska M, Pondel M, Banasik M.   +6 more
europepmc   +1 more source

Angiotensin II Type 1 Receptor Antibodies Are Higher in Lupus Nephritis and Vasculitis than Other Glomerulonephritis Patients. [PDF]

Arch Immunol Ther Exp (Warsz), 2022
Szymczak M, Heidecke H, Żabińska M, Rukasz D, Wiśnicki K, Tukiendorf A, Krajewska M, Banasik M.   +7 more
europepmc   +1 more source